Johnson & Johnson reported a strong Q1 with raised full-year guidance and positive growth across key segments, despite a one-time $6.9 billion charge from the Talc Settlement. Management maintained an optimistic tone, highlighting strategic investments and pipeline advancements. The market is likely to respond positively to the improved outlook and resilient performance.

[1]